Kinetic profile of carbamazepine in an adult Portuguese outpatient population

被引:6
作者
Almeida, AM
Falcao, AC
Sales, F
Leitao, F
Santos, J
Costa, IM
Caramona, MM
机构
[1] Univ Coimbra, Fac Pharm, Pharmacol Lab, P-3000 Coimbra, Portugal
[2] Coimbra Univ Hosp, Dept Neurol, P-3000 Coimbra, Portugal
[3] Coimbra Univ Hosp, Lab Hormonol & Therapeut Drug Monitoring, P-3000 Coimbra, Portugal
关键词
D O I
10.1046/j.1365-2710.1998.00166.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The aim of our work was to define the kinetic profile of carbamazepine (CBZ), in order to improve on dosing schedules through a Bayesian approach. Method: Carbamazepine dose/steady-state trough concentrations data pairs and associated information were collected retrospectively on a population of adult epileptic patients. Results: Fifty patients (under population) with two or more available concentrations (total of 174 determinations) met our inclusion criteria. Patients were taking CBZ (200-1800 mg/day) in mono- or polytherapy regimens. The analysis assumed a one-compartimental model with first-order absorption and elimination, Due to the data source (only trough concentrations were measured as part of hospital routine), the volume of distribution was fixed at 1.19 l/kg. The final estimates for CL were: 0.075 +/- 0.027 (mono- and polytherapy), 0.069+/-0.020 (monotherapy), and 0.106+0.037 l/h/kg (polytherapy). In order to validate these results, we assessed their predictive capacity using 18 new patients (validation population), submitted to the same inclusion criteria and using Prediction-Error analysis. The results suggested a different CL value for our population compared to earlier published clearance values. The results also pointed to an increased metabolic rate associated with polytherapy. The prediction capacity of the optimization method derived from a Portuguese population made in an a priori evaluation indicated a low error (-0.04 mu g/ml), close to the theoretical zero value. Conclusion: Our results provide specific data on CBZ disposition in a Portuguese population and given the wide variability in the literature values, our data may help improve dosing of CBZ in Portuguese patients.
引用
收藏
页码:315 / 321
页数:7
相关论文
共 47 条
[1]  
ALMEIDA AM, 1997, THER DRUG MONIT, V19, P548
[2]  
ALMEIDA AM, 1997, THER DRUG MONIT, V19, P569
[3]   CARBAMAZEPINE DRUG-INTERACTIONS [J].
BACIEWICZ, AM .
THERAPEUTIC DRUG MONITORING, 1986, 8 (03) :305-317
[4]   CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .2. PHENYTOIN, CARBAMAZEPINE, SULTHIAME, LAMOTRIGINE, VIGABATRIN, OXCARBAZEPINE AND FELBAMATE [J].
BATTINO, D ;
ESTIENNE, M ;
AVANZINI, G .
CLINICAL PHARMACOKINETICS, 1995, 29 (05) :341-369
[5]  
BENET LZ, 1995, PHARM BASI THERAPEUT
[6]   Anticonvulsant therapy in aged patients - Clinical pharmacokinetic considerations [J].
Bernus, I ;
Dickinson, RG ;
Hooper, WD ;
Eadie, MJ .
DRUGS & AGING, 1997, 10 (04) :278-289
[7]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[8]   Drug therapy - Antiepileptic drugs [J].
Brodie, MJ ;
Dichter, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) :168-175
[9]  
BRODIE MJ, 1992, EPILEPSIA S1, V33, P13
[10]   COMPARISON OF 2 METHODS IN THE ESTIMATION OF THE PHARMACOKINETIC PARAMETERS OF PHENYTOIN [J].
BUELGA, DS ;
VAZQUEZ, A ;
ALONSO, AC ;
GARCIA, MJ ;
DOMINGUEZGIL, A .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1990, 15 (03) :225-231